Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.68
OREX's Cash to Debt is ranked higher than
56% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. OREX: 2.68 )
Ranked among companies with meaningful Cash to Debt only.
OREX' s Cash to Debt Range Over the Past 10 Years
Min: 1.43  Med: 38.23 Max: No Debt
Current: 2.68
Equity to Asset 0.18
OREX's Equity to Asset is ranked lower than
94% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OREX: 0.18 )
Ranked among companies with meaningful Equity to Asset only.
OREX' s Equity to Asset Range Over the Past 10 Years
Min: -3.15  Med: 0.43 Max: 0.86
Current: 0.18
-3.15
0.86
F-Score: 6
Z-Score: -1.92
M-Score: -4.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -105.37
OREX's Operating margin (%) is ranked lower than
90% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. OREX: -105.37 )
Ranked among companies with meaningful Operating margin (%) only.
OREX' s Operating margin (%) Range Over the Past 10 Years
Min: -107754.55  Med: -4536.58 Max: -54.99
Current: -105.37
-107754.55
-54.99
Net-margin (%) -118.35
OREX's Net-margin (%) is ranked lower than
91% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. OREX: -118.35 )
Ranked among companies with meaningful Net-margin (%) only.
OREX' s Net-margin (%) Range Over the Past 10 Years
Min: -105954.55  Med: -4415.71 Max: -67.59
Current: -118.35
-105954.55
-67.59
ROE (%) -268.85
OREX's ROE (%) is ranked lower than
98% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. OREX: -268.85 )
Ranked among companies with meaningful ROE (%) only.
OREX' s ROE (%) Range Over the Past 10 Years
Min: -235.61  Med: -109.88 Max: -42.04
Current: -268.85
-235.61
-42.04
ROA (%) -24.86
OREX's ROA (%) is ranked lower than
85% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. OREX: -24.86 )
Ranked among companies with meaningful ROA (%) only.
OREX' s ROA (%) Range Over the Past 10 Years
Min: -101.77  Med: -66.46 Max: -19.09
Current: -24.86
-101.77
-19.09
ROC (Joel Greenblatt) (%) -1271.74
OREX's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. OREX: -1271.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OREX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -34518.01  Med: -7367.66 Max: -3874.08
Current: -1271.74
-34518.01
-3874.08
Revenue Growth (3Y)(%) 73.50
OREX's Revenue Growth (3Y)(%) is ranked higher than
97% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OREX: 73.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OREX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -50.00 Max: 73.5
Current: 73.5
0
73.5
EBITDA Growth (3Y)(%) -23.00
OREX's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OREX: -23.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OREX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.8  Med: -23.65 Max: -8
Current: -23
-49.8
-8
EPS Growth (3Y)(%) -18.30
OREX's EPS Growth (3Y)(%) is ranked lower than
77% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. OREX: -18.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OREX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: -20.80 Max: -8.6
Current: -18.3
-55.5
-8.6
» OREX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

OREX Guru Trades in Q1 2015

Steven Cohen 2,048,300 sh (New)
Paul Tudor Jones 37,027 sh (New)
John Burbank 51,980 sh (New)
» More
Q2 2015

OREX Guru Trades in Q2 2015

Jim Simons 420,400 sh (New)
Steven Cohen Sold Out
John Burbank Sold Out
Paul Tudor Jones 14,200 sh (-61.65%)
» More
Q3 2015

OREX Guru Trades in Q3 2015

Seth Klarman 821,363 sh (New)
Jim Simons 2,780,376 sh (+561.36%)
Paul Tudor Jones 11,163 sh (-21.39%)
» More
Q4 2015

OREX Guru Trades in Q4 2015

Jim Simons 1,766,200 sh (-36.48%)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Orexigen Therapeutics Inc

Seth Klarman Buys Pharmaceutical Company's Shares to Fund International Drug Launch Investment will help the company expand its hit weight-loss drug
True to form, Seth Klarman (Trades, Portfolio) purchased a stake in a pharmaceutical company with a sinking stock but a new blockbuster drug ready to push out the door. Read more...

Ratios

vs
industry
vs
history
Forward P/E 8.00
OREX's Forward P/E is ranked higher than
89% of the 409 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.38 vs. OREX: 8.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.15
OREX's P/B is ranked lower than
92% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. OREX: 5.15 )
Ranked among companies with meaningful P/B only.
OREX' s P/B Range Over the Past 10 Years
Min: 0.86  Med: 5.05 Max: 81
Current: 5.15
0.86
81
P/S 4.84
OREX's P/S is ranked lower than
84% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. OREX: 4.84 )
Ranked among companies with meaningful P/S only.
OREX' s P/S Range Over the Past 10 Years
Min: 4.54  Med: 155.00 Max: 1495
Current: 4.84
4.54
1495
PFCF 3.15
OREX's PFCF is ranked higher than
96% of the 481 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.29 vs. OREX: 3.15 )
Ranked among companies with meaningful PFCF only.
OREX' s PFCF Range Over the Past 10 Years
Min: 3.06  Med: 11.00 Max: 35.22
Current: 3.15
3.06
35.22
POCF 3.97
OREX's POCF is ranked higher than
94% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.33 vs. OREX: 3.97 )
Ranked among companies with meaningful POCF only.
OREX' s POCF Range Over the Past 10 Years
Min: 3.88  Med: 21.78 Max: 79.5
Current: 3.97
3.88
79.5
Current Ratio 7.10
OREX's Current Ratio is ranked higher than
86% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. OREX: 7.10 )
Ranked among companies with meaningful Current Ratio only.
OREX' s Current Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.19 Max: 19.3
Current: 7.1
1.99
19.3
Quick Ratio 6.79
OREX's Quick Ratio is ranked higher than
87% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. OREX: 6.79 )
Ranked among companies with meaningful Quick Ratio only.
OREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.19 Max: 19.3
Current: 6.79
1.99
19.3
Days Sales Outstanding 39.18
OREX's Days Sales Outstanding is ranked higher than
82% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. OREX: 39.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
OREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.2  Med: 12.55 Max: 16.9
Current: 39.18
8.2
16.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.65
OREX's Price/Net Cash is ranked higher than
51% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.83 vs. OREX: 9.65 )
Ranked among companies with meaningful Price/Net Cash only.
OREX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.01  Med: 6.03 Max: 391.5
Current: 9.65
1.01
391.5
Price/Net Current Asset Value 5.47
OREX's Price/Net Current Asset Value is ranked higher than
57% of the 630 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.78 vs. OREX: 5.47 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OREX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1  Med: 5.91 Max: 87
Current: 5.47
1
87
Price/Tangible Book 5.13
OREX's Price/Tangible Book is ranked lower than
63% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. OREX: 5.13 )
Ranked among companies with meaningful Price/Tangible Book only.
OREX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.99  Med: 5.68 Max: 78.3
Current: 5.13
0.99
78.3
Price/Median PS Value 0.03
OREX's Price/Median PS Value is ranked higher than
100% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.11 vs. OREX: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
OREX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.80 Max: 9.19
Current: 0.03
0.04
9.19
Price/Graham Number 4.21
OREX's Price/Graham Number is ranked lower than
80% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. OREX: 4.21 )
Ranked among companies with meaningful Price/Graham Number only.
OREX' s Price/Graham Number Range Over the Past 10 Years
Min: 12.69  Med: 12.69 Max: 12.69
Current: 4.21
Earnings Yield (Greenblatt) (%) -46.90
OREX's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. OREX: -46.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OREX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -49.24  Med: 155.00 Max: 3901
Current: -46.9
-49.24
3901

More Statistics

Revenue(Mil) $42
EPS $ -0.40
Beta2.67
Short Percentage of Float18.69%
52-Week Range $1.39 - 9.37
Shares Outstanding(Mil)145.44

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 36 74 156
EPS($) -0.51 -0.34 0.21
EPS without NRI($) -0.51 -0.34 0.21

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:JXS.Germany,
Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 

More From Other Websites
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 08 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure Feb 04 2016
Orexigen Therapeutics to Speak at Upcoming Investor Conferences Feb 02 2016
8 Stocks Under $10 Making Big Moves Higher Jan 22 2016
Orexigen Targets Profitability by 2018, Focus on Contrave Jan 12 2016
Orexigen announces 2016 financial outlook and key priorities Jan 11 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2016
Orexigen announces 2016 financial outlook and key priorities Jan 11 2016
Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP,... Jan 08 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 08 2016
Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP,... Jan 08 2016
Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare Conference Jan 05 2016
Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare Conference Jan 05 2016
10 Biotechs Short Sellers Are Betting Against Dec 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK